A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
55–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
The prospective participant must meet, at least, all of the criteria below (among others determined by the study staff) to be eligible for study participation.
The participant:
Has mild-to-moderate Alzheimer's Disease (AD), OR is considered cognitively normal;
Has been on stable doses of any regularly used medications for 4 weeks prior to study start;
Must have been on a stable dose for 12 weeks prior to study start, of any medications taken for AD.
You may not be if
If the prospective participant meets any of the criteria below (among others determined by the study staff) they will NOT be eligible for study participation.
The participant:
Is living in a nursing home or skilled nursing facility;
Has severe AD;
Cannot undergo MRI;
Cannot undergo PET scans;
Has a history of neurological or neurodegenerative disorders, other than AD within 2 years prior to study start;
Has taken Tacrine or anti-parkinsonian medications within 3 months of study start;
Has taken corticosteroids, blood thinners, narcotic analgesics, benzodiazepines, or certain antihistamines within 1 month of study start;
Initiates, discontinues, or changes the dose of any AD treatment during the study.
